This page shows the latest DMD news and features for those working in and with pharma, biotech and healthcare.
A number of companies are seeking to develop therapies for DMD as the therapy area becomes increasingly more competitive. ... Vyondys 53 is Sarepta’s second approved DMD therapy after Exondys 51 (eteplirsen).
The approval of Viltepso was based on two clinical studies with a total of 32 patients with genetically confirmed DMD. ... This represents around 8% of the overall DMD population, while those with the exon 51 mutation account for around 13%.
DMD causes progressive weakness and atrophy of skeletal, heart and pulmonary muscles, and overwhelmingly affects males. ... NS Pharma’s drug is designed to treat DMD patients with exon 53 mutations – the exact same mutation which rival Sarepta’s
Extends company's cash runway up until 2021. Solid Biosciences has sacrificed a third of its staff as it desperately tries to cling to its troubled Duchenne muscular dystrophy (DMD) programme. . ... The FDA halted the IGNITE DMD trial following a report
DMD – a rare muscle-wasting disease that mostly affects boys and typically is fatal by age 30 – is caused by a defect in the gene coding for dystrophin, a protein found ... functionality of the mutated protein and avoiding the contraction-induced
The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD. ... DMD is one of the most common fatal genetic disorders, affecting around one in every 3, 500-5, 000 male births worldwide.
More from news
Approximately 9 fully matching, plus 46 partially matching documents found.
Like other DMDs, metal exposure should be avoided,” adds Ben- Amor, who has been involved in MS research and business operations for 20 years.
additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “early” approval. ... $20.31 before settling at around $19.00. Prosensa has been busy since drisapersen failed a
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”. ... we seek to bring disease-modifying
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Benjamin is a trustee and patient advocate for DMD Pathfinders and has recently completed a Masters in Scientific Communications.
for instance to treat haemophilia, rare ophthalmic disorders and for Duchenne muscular dystrophy/DMD), genetic therapies are likely to represent a revolution in medicine over the coming years. ... However, in most areas where genetic treatments are being
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...